CORonary Diet Intervention With Olive Oil and Cardiovascular PREVention

Combined apparition of hard cardiovascular events (myocardial infarction, revascularization, ischemic stroke, documented peripheral artery disease or cardiovascular death) after a median follow-up of 7 years.

Data from clinical and/or diagnostic tests will be analyzed

Concentration of LDL cholesterol in blood samples

Comparison of Atherogenic ratio, and Total cholesterol/HDL and LDL/HDL during the study

Study of the metabolism of carbohydrates during the trial

Study of blood pressure in response to the study

Appearance of malignancy

Cognitive decline will be evaluated by validated questionnaires

Incidence of cardiac death, myocardial infarction, angina event, coronary revascularization or cardiac transplant, stroke, symptomatic heart failure, or any other clinical manifestation of cardiovascular event.

Incidence of cardiac death , myocardial infarction , unstable angina , revascularization, heart failure, heart transplantation, cardiac arrest

Incidence of type 2 Diabetes Mellitus during the study

Clinical features of metabolic disease: Metabolic Syndrome, Metabolic Phenotypes of Obesity or other classifications based on anthropometric features will be assessed during the study

Changes in the percentage of different families of Microbiota will be analyzed during the study, and their impact on clinical events.

Study of relationship between existing or new Arrhythmias on clinical events

Individual apparition of hard cardiovascular events:

• myocardial infarction
• revascularization
• ischemic stroke
• documented peripheral artery disease
• cardiovascular death

Global metabolomics in plasma, as well as techniques targeting specific sets of metabolites such as lipid-based lipid species, protein by proteomics, etc.

Specific metabolomics in plasma fractions, specific bioparticles such as lipoproteins or specific cells, lipidomics, proteomics, targeted metabolomics, etc

Changes in Gene Expression using transcriptomic techniques such as gene expression microarrays, quantitative PCR, GeneChip, etc

Different physiological processes or metabolic pathways related to inflammation and oxidative stress will be studied

Metabolism of advanced glycation end products.

Impact of mineral metabolism on atherosclerosis

Cardiac function studies by Echocardiography at baseline and during the study

Study of endothelial microparticles (vesicles formed from endothelial cells membrane after injury). The quantification of the EPCs and EMPs will be performed by flow cytometry

• Differential impact on certain subgroups: Sex, age, anthropometry, genetics, genomics, metabolism of immediate principles, cardiovascular risk factors, cancer, vascular function

Endothelium response to ischemia in the brachial artery. Area under the curve, flow peak and time to maximum flow will be performed

Influence of genetic data in the development clinical outcomes

Postprandial lipemia study based on oral fat tolerance test depending on clinical and genetic variables

Clinical events not qualifying as primary endpoint nor in the secondary objectives 1 and 2, especially those associated with cardiovascular disease

Differential impact on certain subgroups: Sex, age, anthropometry, genetics, genomics, metabolism of immediate principles, cardiovascular risk factors, cancer, vascular function

Additional secondary objectives will be carried out in light of current and/or future knowledge of ischemic heart disease risk factors, prognostic factors and pathophysiological pathways, and will include, but not be limited to, endothelial function, inflammation, cell biology, molecular biology, proteomics, genetics and epigenetics